
Need professional-grade analysis? Visit stockanalysis.com
$74.81T
41.92
5,195
N/A
| Ratio | 1W | 1M | 3M | 6M | 1Y | 5Y | Score |
|---|---|---|---|---|---|---|---|
| Ulcer | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 |
Samsung Biologics Co Ltd (207940) trades on KO in KRW. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at KRW1000000.00.
Over the past year, 207940 has traded between a low of KRW1000000.00 and a high of KRW1000000.00.
Samsung Biologics Co Ltd has a market capitalization of $74.81T, with a price-to-earnings ratio of 41.92.
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Side-by-side comparison against top Healthcare peers.